ReviewBioImpacts : BI2026
Recent advances in SLN and NLC-based lipid nanoparticles for cosmetic, dermal, and transdermal drug delivery: A comprehensive review.
Review in BioImpacts : BI, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent advances in nanotechnology have positioned solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) as promising platforms for dermal and transdermal drug delivery. This review critically highlights emerging breakthroughs that go beyond the conventional advantages of lipid nanoparticles. SLNs, composed of physiologically compatible solid lipids, provide improved drug stability and controlled release; however, their clinical utility is often constrained by limited drug loading, drug expulsion during storage, and highly ordered crystalline structures. To overcome these drawbacks, second-generation NLCs incorporate both solid and liquid lipids, creating an imperfect lipid matrix that significantly enhances loading capacity, minimizes drug leakage, and enables tunable release kinetics. Recent formulation innovations including precision high-pressure homogenization, microfluidic-assisted production, and optimized hot/cold homogenization approaches have enabled tighter particle size control, improved batch reproducibility, and better long-term stability. In parallel, surface engineering strategies such as ligand functionalization, polymer coating, and incorporation of natural bioactives have demonstrated enhanced skin targeting, deeper stratum corneum penetration, and prolonged dermal retention. Notably, recent preclinical and translational studies report improved therapeutic outcomes in acne, psoriasis, fungal infections, inflammatory disorders, wound healing, hyperpigmentation, and melanoma-related skin conditions when compared with conventional topical systems. Despite these advances, important translational gaps remain, including large-scale manufacturing challenges, regulatory uncertainties, and limited clinical validation. By integrating recent technological breakthroughs with application-focused evidence, this review provides a forward-looking perspective on the evolving role of SLNs and NLCs as next-generation lipid nanocarriers for dermatological therapy and advanced skin care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.